Theriva Biologics Inc (TOVX)

[pistol1p]

IMO:

At 12 months the reduction in the relapse rate, in the Trimesta plus Copaxone treatment group, was 47% lower than in the placebo plus Copaxone group. The P value, for statistical significance, was: <.05. Thus the 47% reduction was statistically significant, therefore the outcome is less likely to have happened by chance.

At 24 months the reduction in the relapse rate, in the Trimesta plus Copaxone treatment group, was 32% lower than in the placebo plus Copaxone group. The P value, for statistical significance, was: > .05. Thus the 32% reduction was not statistically significant, therefore it is unclear if the 32% reduction was an effect of the Trimesta, or was just a chance occurrence.